性别与年龄对局部食管胃癌化疗疗效、毒性及生存的影响:四项大型随机试验3265例个体患者数据的汇总分析
该研究汇总四项前瞻性随机对照试验(OE02、OE05、MAGIC、ST03)的3265例局部食管胃癌患者个体数据,采用两阶段荟萃分析。结果显示女性较男性总生存(HR 0.78;p<0.001)和疾病特异性生存(HR 0.78;p<0.001)显著改善,但≥III级恶心、呕吐、腹泻发生率显著更高;≥70岁与<70岁患者生存无显著差异,老年患者应依据体能状况接受相同治疗方案。
要点
- 女性局部食管胃癌患者化疗后生存显著优于男性,但胃肠道毒性更高
- ≥70岁与<70岁患者生存无显著差异,老年患者不应仅因年龄被排除强化治疗
- 接受切除的患者中,老年和女性更易达到有利的Mandard肿瘤退缩分级
核心结论
- 女性局部食管胃癌患者化疗后总生存和疾病特异性生存显著优于男性,但≥III级胃肠道毒性发生率更高。
- ≥70岁患者与<70岁患者生存相当,应根据体能状况而非年龄决定是否采用相同治疗范式。
研究设计与样本
- 汇总四项前瞻性随机对照试验(OE02、OE05、MAGIC、ST03)的个体患者数据,采用两阶段荟萃分析。
- 生存分析共纳入3265例患者:男性2668例(82%)、女性597例(18%);<70岁2627例(80%)、≥70岁638例(20%)。
- 所有分析均校正了所接受的化疗类型。
主要发现
- 女性较男性总生存显著改善(HR 0.78;p<0.001),疾病特异性生存也显著改善(HR 0.78;p<0.001)。
- ≥70岁与<70岁患者总生存(HR 1.11;p=0.045)和疾病特异性生存(HR 1.01;p=0.821)无显著差异。
- 接受切除的患者中,老年患者较年轻患者更易达到有利的Mandard肿瘤退缩分级(15% vs 10%;p=0.03)。
- 女性较男性更易达到有利的Mandard肿瘤退缩分级(14% vs 10%;p=0.10)。
- 女性较男性≥III级恶心(10% vs 5%;p≤0.001)、呕吐(10% vs 4%;p≤0.001)和腹泻(9% vs 4%;p≤0.001)发生率显著更高。
临床怎么用
- 女性局部食管胃癌患者化疗后生存更优但胃肠道毒性更高,临床应加强女性患者的止吐和腹泻管理。
- ≥70岁患者不应仅因年龄被排除强化化疗或手术,应依据体能状况个体化评估后考虑相同治疗范式。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: There is a lack of large-scale randomised data evaluating the impact of sex and age in patients undergoing chemotherapy followed by potentially curative surgery for oesophagogastric cancer. PATIENTS AND METHODS: Individual patient data from four prospective randomised controlled trials were pooled using a two-stage meta-analysis. For survival analysis, hazard ratios (HRs) were calculated for patients aged <70 and ≥ 70 years, as well as between males and females. Mandard tumour regression grade (TRG) and, ≥grade III toxicities were compared using logistic regression models to calculate odds ratios. All analyses were adjusted for the type of chemotherapy received. RESULTS: 3265 patients were included for survival analysis (2668 [82%] male, 597 [18%] female; 2627 (80%) <70 years, 638 (20%) ≥70 years). A significant improvement in overall survival (OS) (HR: 0.78; p < 0.001) and disease-specific survival (DSS) (HR: 0.78; p < 0.001) was observed in females compared with males. No significant differences in OS (HR: 1.11; p = 0.045) or DSS (HR: 1.01; p = 0.821) were observed in older patients compared with younger patients. For patients who underwent resection, older patients (15% vs 10%; p = 0.03) and female patients (14% vs 10%, p = 0.10) were more likely to achieve favourable Mandard TRG scores. Females experienced significantly more ≥grade III nausea (10% vs 5%; p≤0.001), vomiting (10% vs 4%; p≤0.001) and diarrhoea (9% vs 4%; p≤0.001) than males. CONCLUSIONS: In this large pooled analysis using prospective randomised trial data, females had significantly improved survival while experiencing more gastrointestinal toxicities. Older patients achieved comparable survival to younger patients and thus, dependent on fitness, should be offered the same treatment paradigm.
引用
- Athauda A, Nankivell M, Langley RE, et al. Impact of sex and age on chemotherapy efficacy, toxicity and survival in localised oesophagogastric cancer: A pooled analysis of 3265 individual patient data from four large randomised trials (OE02, OE05, MAGIC and ST03). Eur J Cancer. 2020. PMID: 32745964. doi:10.1016/j.ejca.2020.06.005
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。